SAB Biotherapeutics announces new CEO
Sioux Falls-based SAB Biotherapeutics Inc. has a new CEO.
Sioux Falls-based SAB Biotherapeutics Inc. has a new CEO.
Here’s a look at this week’s Movers & Shakers.
Sioux Falls-based SAB Biotherapeutics has secured a private placement offering that will provide up to $130 million to advance development of its new treatment for Type 1 diabetes.
The U.S. Food and Drug Administration has cleared Sioux Falls-based SAB Biotherapeutics to move ahead with “fast track designation” for its therapeutic showing promising results in treating influenza.
She led efforts to bring drugs to market at Pfizer Inc. and Sanofi. Now, she’s helping bring a Sioux Falls biotech company’s therapeutics to patients.
From going public to navigating the pandemic, we sat down with SAB Biotherapeutics CEO Eddie Sullivan for our latest CEO Series.
Sioux Falls-based SAB Biotherapeutics provided updates on its therapeutics for COVID-19, influenza and type 1 diabetes in reporting its year-end earnings last week.
The COVID-19 antibody treatment developed by Sioux Falls-based SAB Biotherapeutics has neutralized the Omicron variant in FDA laboratory testing, the company reported.
SAB Biotherapeutics is reporting promising news around its new treatment for the influenza virus.
Sioux Falls-based SAB Biotherapeutics has released its first earnings report since becoming a publicly traded company.